Ann Liver Transplant.  2022 Nov;2(2):151-156. 10.52604/alt.22.0020.

Liver transplantation for primary hepatic angiosarcoma: A report of two cases

• Kim SM
• Ahn CS
• Moon DB
• Ha TY
• Song GW
• Jung DH
• Park GC
• Kang WH
• Yoon YI
• Hwang S

• KMID: 2560911
• DOI: http://doi.org/10.52604/alt.22.0020

Abstract

Liver transplantation (LT) is an accepted treatment for some hepatic malignancies including hepatocellular carcinoma. We herein present two cases of primary hepatic angiosarcoma (PHAS) who underwent deceased donor LT (DDLT). The first case was a 61-year-old male who was diagnosed with cryptogenic liver cirrhosis. He underwent transarterial chemoembolization for multiple liver nodular lesions. Because of progressive hepatic failure with a model for end-stage liver disease (MELD) score of 40, he underwent DDLT. PHAS was not diagnosed for the explant liver at the time of DDLT. However, it was confirmed through immunohistochemical staining studies at 3 months after LT. The patient passed away at 5 months after LT due to tumor progression. The second case was a 74-year-old male with cryptogenic liver cirrhosis. He suffered from hepatorenal syndrome with a MELD score of 40. Thus, he underwent DDLT. PHAS was diagnosed for the explant liver at the time of DDLT. At 6 months after LT, tumor recurrence was identified and the patient passed away at 12 months after LT due to tumor progression. This is the first report of two adult cases of LT recipients with PHAS in Korea. If we had recognized the possibility of PHAS, the decision to perform LT would not be taken easily despite MELD score of 40. Our experience suggests that PHAS is still a contraindication of LT.

Keyword

Angiosarcoma; Liver transplantation; Recurrence; Survival; Prognosis